Breaking News Instant updates and real-time market news.

TXN

Texas Instruments

$129.82

-1.11 (-0.85%)

, DFS

Discover

$81.61

1.16 (1.44%)

13:33
10/22/19
10/22
13:33
10/22/19
13:33

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Texas Instruments (TXN), consensus $1.42... Discover (DFS), consensus $2.28... Chipotle Mexican Grill (CMG), consensus $3.22... Snap (SNAP), consensus (5c)... Teradyne (TER), consensus 70c... Whirlpool (WHR), consensus $3.89... Skechers U.S.A. (SKX), consensus 70c... Six Flags (SIX), consensus $2.31... Navient (NAVI), consensus 57c... iRobot (IRBT), consensus 52c.

TXN

Texas Instruments

$129.82

-1.11 (-0.85%)

DFS

Discover

$81.61

1.16 (1.44%)

CMG

Chipotle

$832.60

-19.28 (-2.26%)

SNAP

Snap

$14.10

-0.48 (-3.29%)

TER

Teradyne

$59.18

-0.89 (-1.48%)

WHR

Whirlpool

$161.17

0.63 (0.39%)

SKX

Skechers

$37.97

0.49 (1.31%)

SIX

Six Flags

$51.41

-0.43 (-0.83%)

NAVI

Navient

$12.09

0.12 (1.00%)

IRBT

iRobot

$55.39

-0.31 (-0.56%)

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 21

    Nov

  • 09

    Dec

TXN Texas Instruments
$129.82

-1.11 (-0.85%)

10/16/19
LOOP
10/16/19
NO CHANGE
Target $140
LOOP
Buy
Loop Capital sees cautious but optimistic tone from Texas Instruments earnings
Loop Capital analyst Cody Acree keeps his Buy rating and $140 price target on Texas Instruments ahead of its Q3 results next week. The analyst anticipates a "cautious but optimistic" tone from the earnings call, noting that many of its segments are starting to trend more positively. Acree adds that the end of estimate cuts is likely within sight for Texas Instruments as 2020 is shaping up to be a strong year for semiconductor demand, even though the near term is still overshadowed by the uncertainty related to U.S.-China trade relations.
10/14/19
LBOW
10/14/19
NO CHANGE
Target $84
LBOW
Buy
Longbow says Arrow shares' reaction 'surprisingly underwhelming' to good TI news
Longbow analyst Shawn Harrison called Arrow Electronics (ARW) "the clear winner" from news of of Texas Instruments' (TXN) consolidation of over $6B of distribution resales. The analyst, who noted that TI's plans to consolidate to six global distributors by the end of 2020 will leave Arrow as its sole fulfillment partner in North America, Europe, and Asia excluding Japan, thinks the stock's reaction thus far to the news "has been surprisingly underwhelming." Harrison maintains a Buy rating and $84 price target on Arrow shares.
10/04/19
LBOW
10/04/19
DOWNGRADE
LBOW
Neutral
Longbow downgrades Avnet to Neutral after TI plans end to distribution pact
Longbow analyst Shawn Harrison downgraded Avnet (AVT) to Neutral from Buy, citing uncertainty created by Texas Instruments' (TXN) decision to end its distribution relationship with the company. Avnet now finds itself in "an unenviable position of finding new significant cost cuts while already halfway through massive cost reductions," said the analyst, who estimates the gross profit impact is $150M, or greater than $1.00 per share of EPS. Harrison added that he expects TI to migrate the business to Arrow Electronics (ARW)
10/18/19
OPCO
10/18/19
NO CHANGE
Target $140
OPCO
Outperform
Texas Instruments price target raised to $140 from $130 at Oppenheimer
Oppenheimer analyst Rick Schafer raised his price target for Texas Instruments to $140 from $130 and maintained an Outperform rating ahead of the company's earnings report on October 22. In a research note to investors, Schafer says he sees Q3 results in line with consensus and its Q4 outlook in line with the Street's view, adding that he expects comps to ease in Q4.
DFS Discover
$81.61

1.16 (1.44%)

06/19/19
BOFA
06/19/19
INITIATION
Target $82
BOFA
Neutral
Discover reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg reinstated coverage of Discover Financial Services with a Neutral rating and $82 price target. The analyst believes cyclical credit concerns remain a "potent overhang" on the shares. As a result, he sees limited potential for multiple expansion from current stock levels.
07/24/19
WELS
07/24/19
NO CHANGE
Target $88
WELS
Market Perform
Discover price target raised to $88 from $82 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for Discover to $88 from $82 following another "strong quarter." The analyst reiterates a Market Perform rating on the shares.
07/24/19
NOMU
07/24/19
NO CHANGE
Target $96
NOMU
Buy
Discover price target raised to $96 from $86 at Nomura Instinet
Nomura Instinet analyst Bill Carcache raised his price target for Discover Financial Services to $96 from $86 saying he expects the stock to continue rising on the back of the company's Q2 results. The report was characterized by a combination of stronger revenues and lower provision expense, Carcache tells investors in a research note. He now has "even greater confidence" that an accommodative Federal Reserve and "healthy" consumer will enable Discover to sustain double-digit earnings growth. The analyst keeps a Buy rating on the shares.
07/08/19
DBAB
07/08/19
INITIATION
Target $87
DBAB
Hold
Discover reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Dave Rochester reinstated coverage of Discover Financial with a Hold rating and $87 price target.
CMG Chipotle
$832.60

-19.28 (-2.26%)

10/18/19
RHCO
10/18/19
NO CHANGE
Target $920
RHCO
Buy
Chipotle price target raised to $920 from $900 at SunTrust
SunTrust analyst Jake Bartlett raised his price target on Chipotle to $920 and kept his Buy rating ahead of its Q3 earnings as part of his broader research note previewing the quarter for the Restaurants group. The analyst expects the company to beat on comps and issue a "strong" same-store-sales guidance for Q4, adding that its outlook for accelerating developments in FY20 should lead to upside in the stock price. Bartlett further notes that in addition to Chipotle's prior same-store-sales drivers, including delivery, digital order/pickup, and rewards programs, the national launch of Carne Asada has "significantly" increased its check mix while driving more traffic.
10/18/19
10/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Neutral from Sell at Citi with analyst Adam Spielman saying he now expects "less bad" cigarette volumes next year. 2. Snap (SNAP) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post saying the stock has sold off despite "solid" industry and advertising spend channel checks. 3. Chipotle (CMG) upgraded to Neutral from Underperform at BofA/Merrill with analyst Gregory Francort saying he expects the company to generate better comps and margins over the near term given its "strong" sales momentum and normalizing avocado prices, even though he is "struggling" with the valuation on the stock. 4. Republic Services (RSG) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Feniger calling the stock "a more balanced way" to gain exposure to the theme of higher disposal pricing than peer Waste Management (WM), which he downgraded this morning. 5. Waste Connections (WCN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Sean Eastman saying he expects Waste Connections to report an in-line Q3, and sees 2019 guidance remaining intact. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/19
BTIG
10/21/19
NO CHANGE
Target $890
BTIG
Buy
Chipotle price target raised to $890 from $845 at BTIG
BTIG analyst Peter Saleh raised his price target on Chipotle to $890 and kept his Buy rating, saying that investors should not be "blinded" by the valuation on the stock as the company remains in the "middle innings" of its turnaround thanks to its efforts on digital ordering, menu innovation, and marketing. The analyst maintains that annual earnings of $25 per share are "achievable" as sales recover, leading to the expansion of restaurant and operating margins.
10/21/19
LOOP
10/21/19
NO CHANGE
Target $950
LOOP
Buy
Chipotle price target raised to $950 from $860 at Loop Capital
Loop Capital analyst Lynne Collier raised her price target on Chipotle to $950 and kept her Buy rating ahead of its earnings tomorrow. The analyst expects the company's national launch of Carne Asada to be a "hit" and is also raising her Q3 SSS forecast to 9.5% from 7.9% while boosting her Q3 earnings view by 16c to $3.20. Collier contends that Chipotle's momentum can continue thanks to its growth in digital ordering, improving operations, and menu innovation.
SNAP Snap
$14.10

-0.48 (-3.29%)

10/21/19
CLVD
10/21/19
NO CHANGE
CLVD
Snap advertiser outlook seen getting more bullish, says Cleveland Research
Cleveland Research analyst Chandler Converse said his channel checks indicate that advertisers' outlook on Snap (SNAP) appears more bullish in recent feedback, adding that Q3 "sounds stronger than expected" as the company seems to be executing better. Converse also said in a note on social advertising checks that Pinterest (PINS) partners point to growing advertisers and strong pipelines of net new clients. Converse does not have ratings on Snap or Pinterest shares.
10/18/19
10/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Investors Real Estate (IRET) initiated with an Outperform at Raymond James. 2. Pinterest (PINS) and Snap (SNAP) initiated with a Neutral at MKM Partners. 3. Intellicheck (IDN) initiated with a Buy at B. Riley FBR. 4. Welbilt (WBT) initiated with a Market Perform at BMO Capital. 5. Endava (DAVA) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/19
LITP
10/21/19
INITIATION
Target $20
LITP
Buy
Snap initiated with a Buy at LightShed Partners
LightShed Partners analyst Rich Greenfield initiated coverage of Snap with a Buy rating and $20 price target. In June, when formerly with BTIG, Greenfield had raised his price target on Snap to $20 and kept his Buy rating on the stock.
10/21/19
FBCO
10/21/19
NO CHANGE
Target $21
FBCO
Outperform
Snap ads forecast raised for Q3 at Credit Suisse
Credit Suisse analyst Stephen Ju has raised his Snap Ads forecast for Q3 by $10M based on positive feedback from advertisers. The analyst believes Snap has come full circle to begin delivering on the investment thesis at the time of its public offering and he is looking forward to a sustained period of lower gyrations to its users along with revenue growth driven by primarily ad impressions. Ju reiterates an Outperform rating for Snap, while raising his price target on the shares to $21 from $20 given potential for better-than-expected user growth with a revamped Android app released in more geographies, potential for better-than-expected ad revenue on ramping ad load growth, and as Snap is a scarce asset that offers advertisers access to a coveted younger demographic.
TER Teradyne
$59.18

-0.89 (-1.48%)

07/25/19
STFL
07/25/19
DOWNGRADE
Target $53
STFL
Hold
Teradyne downgraded to Hold from Buy at Stifel
Stifel analyst Brian Chin downgraded Teradyne to Hold from Buy while raising his price target for the shares to $53 from $52. The analyst says that following the company's Q2 results, the stock has now outstripped his sum-of-the-parts based target price. Robotics is an attractive long-term opportunity, but Teradyne's growth has now been revised down twice in the span of about six months, Chin tells investors in a research note. He believes the company's current valuation "seems to ignore the deteriorating visibility in this key growth segment." As such, Chin views Teradyne's risk/reward as less favorable at current share levels.
10/01/19
KEYB
10/01/19
NO CHANGE
KEYB
KeyBanc makes four Semiconductor rating changes after trip to Asia
KeyBanc analyst Weston Twigg made four rating changes in the Semiconductors space after his quarterly trip to Asia revealed overall demand trends, while still weak, "are not getting worse." The analyst was encouraged to find inventories are beginning to normalize and that expectations are for normal seasonality in Q4. As a result, he upgraded Analog Devices (ADI), Microchip (MCHP), and NXP Semiconductors (NXPI) to Overweight from Sector Weight. Conversely, the China insourcing trends at Huawei and other manufacturers are accelerating faster than Twigg had expected, which results in his downgrade of Xilinx (XLNX) to Sector Weight from Overweight. The analyst also recommends building long-term positions in semi-cap and memory stocks like KLA-Tencor (KLAC), Teradyne (TER), Micron Technology (MU), MKS Instruments (MKSI), Entegris (ENTG), Applied Materials (AMAT) and Lam Research (LRCX). Lastly, Twigg says that initial demand for Apple's (AAPL) new iPhone "appears to be slightly worse than expected."
07/25/19
FBCO
07/25/19
NO CHANGE
Target $55
FBCO
Neutral
Teradyne price target raised to $55 from $45 at Credit Suisse
Credit Suisse analyst John Pitzer raised his price target for Teradyne to $55 from $45 following quarterly results. The analyst reiterates a Neutral rating on the shares.
09/23/19
SBSH
09/23/19
UPGRADE
Target $68
SBSH
Buy
Advanced Energy upgraded to Buy from Neutral at Citi
Citi analyst Atif Malik upgraded Advanced Energy Industries (AEIS) to Buy from Neutral and raised his price target for the shares to $68 from $55. The analyst is moving to a "more offensive" Semiconductor Capital Equipment stance as he believes the memory market is showing signs of recovery and that 5G logic investments are accelerating, which adds confidence to his 2020/2021 wafer-fab equipment recovery thesis. Malik's top equipment picks remain Lam Research (LRCX) and Applied Materials (AMAT). He upgraded Advanced Energy to Buy and moved MKS Instruments (MKSI) to his favorite SMID cap pick. The analyst also likes KLA-Tencor (KLAC), Teradyne (TER) and Advanced Energy on their "5G appeal."
WHR Whirlpool
$161.17

0.63 (0.39%)

09/26/19
JPMS
09/26/19
UPGRADE
Target $172
JPMS
Overweight
JPMorgan upgrades Whirlpool to Overweight, boosts price target to $172
JPMorgan analyst Michael Rehaut upgraded Whirlpool (WHR) to Overweight from Neutral and raised his price target for the shares to $172 from $155. The analyst expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. Further, he thinks point to steel prices will remain "at bay" and that Whirlpool's European operations will "finally" turn a small profit in the second half of 2019. In addition, Rehaut views the stock's valuation as inexpensive. The analyst this morning also downgraded Beacon Roofing Supply (BECN) to Underweight from Neutral. His top picks in the Building Products sector remain Stanley Black & Decker (SWK) and Fortune Brands (FBHS).
10/15/19
BUCK
10/15/19
NO CHANGE
Target $150
BUCK
Neutral
Buckingham backs Neutral on Whirlpool following AHAM data
Buckingham analyst Megan McGrath maintained a Neutral rating and $150 price target on Whirlpool shares after the Association of Home Appliance Manufacturers, or AHAM, released "strong" U.S. appliance shipment data for the month of September. McGrath noted that AHAM 6 shipment growth in the month fell "slightly," a deterioration from the high single digit growth reported last month, and as a result is keeping her third quarter estimates unchanged at this time. The analyst noted that her revenue growth estimate for Whirlpool's North America business in Q3 is 2.5%, adding that if the company was able to gain share or maintain mid-single digit pricing growth, there could be "some upside" to her estimates. McGrath said her Neutral rating is, in part, based on "slow demand" in the U.S. market and concerns over pricing if demand continues to be lackluster, as well as a slowing end market in Europe.
09/26/19
09/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Outperform from Market Perform at Wells Fargo analyst Timothy Willi saying the company's fundamentals remain strong while investor sentiment is "overly negative and close to inflecting." 2. Whirlpool (WHR) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Rehaut saying he expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at BMO Capital with analyst Amit Sharma saying Truly is "primed to capture" strong consumer demand and higher distribution/shelf space for hard seltzer. 4. AbbVie (ABBV) upgraded to Buy from Neutral at Citi with analyst Andrew Baum saying he believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." 5. Hologic (HOLX) upgraded to Buy from Neutral at BofA/Merrill with analyst Ivy Ma saying she sees the company being on "steadier footing with organic growth upside in FY20" thanks to its tuck-in acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/19
JPMS
09/26/19
UPGRADE
Target $172
JPMS
Overweight
Whirlpool upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Rehaut upgraded Whirlpool to Overweight from Neutral and raised his price target for the shares to $172 from $155.
SKX Skechers
$37.97

0.49 (1.31%)

07/22/19
ARGS
07/22/19
NO CHANGE
ARGS
Hold
Skechers' next several quarters to be weighed by DTC investment, says Argus
Argus analyst John Staszak is keeping his Hold rating on Skechers in spite of its better than expected Q2 results, saying he sees the company's increased investment in direct-to-consumer business and its international operations to weigh on its margins over the next few quarters. The analyst is also worried about the impact of the China trade dispute and the softer economy in Europe, keeping his FY19 and FY20 EPS estimates unchanged at $1.90 and $2.20.
07/19/19
SUSQ
07/19/19
NO CHANGE
Target $42
SUSQ
Positive
Skechers price target raised to $42 from $37 at Susquehanna
Susquehanna analyst Sam Poser raised his price target on Skechers to $42 from $37 following strong Q2 results. The analyst noted its strong Q3 guidance showing it is making good progress in controlling costs, managing inventory, and driving more profitability through a willingness to better manage sales growth. Poser reiterated his Positive rating on Skechers shares.
07/19/19
07/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Post Holdings (POST) upgraded to Overweight from Neutral at Piper Jaffray with analyst Michael Lavery saying he expects "good" organic sales growth of 2%-3%) and still consider Post's portfolio attractive for cash generation. 2. Philip Morris (PM) upgraded to Overweight from Equal Weight at Barclays with analyst Gaurav Jain saying the company's new fiscal 2019 revenue growth guidance ex-currency of 6% is towards the higher end in staples. 3. KBR (KBR) upgraded to Outperform from Market Perform at Cowen with analyst Gautam Khanna citing abating overhangs, strong sales, an extreme sum-of-the-parts discount, and improving balance sheet flexibility. Khanna raised his price target to $31 from $23 on KBR shares. 4. WW (WW) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the improving sentiment toward the company's brands, taglines, and programs garnered from the Davidson Brand Sentiment Analysis as the company has already posted improved recruitment trends. 5. Skechers (SKX) upgraded to Outperform from Neutral at Wedbush. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/19
WEDB
07/19/19
UPGRADE
WEDB
Outperform
Skechers upgraded to Outperform from Neutral at Wedbush
SIX Six Flags
$51.41

-0.43 (-0.83%)

10/04/19
10/04/19
NO CHANGE

Cedar Fair told Wells Fargo analyst it is not looking to be sold
10/04/19
JEFF
10/04/19
NO CHANGE
Target $57
JEFF
Hold
Jefferies doesn't see Six Flags paying over $68 per share for Cedar Fair
The potential acquisition of Cedar Fair (FUN) by Six Flags Entertainment (SIX) brings "modestly positive" outcomes from a financial perspective, but more profound benefit strategically, Jefferies analyst David Katz tells investors in a research note. The potential merger with, if true, is more transformative than Six Flags' prior deals, adds the analyst. His broad assumptions include a $68 per share offer for Cedar Fair based on a neutral enterprise value to EBITDA multiple to Six Flags. Cedar Fun closed Thursday up $1.33 to $61.05. Said differently, the analyst assumes Six Flags would not pay higher than its current valuation of 10.3 times estimated 2020 EBITDA. Katz keeps a Hold rating on Six Flags with a $57 price target.
10/04/19
WELS
10/04/19
NO CHANGE
WELS
Outperform
Six Flags an aggressive buy as Cedar Fun deal very unlikely, says Wells Fargo
While no specific comment was made regarding the Reuters article of Six Flags Entertainment (SIX) making a bid, Cedar Fair (FUN) management stated that the company is not looking to be sold, Wells Fargo analyst Timothy Conder told investors last night in a research note. Cedar Fair management conducted scheduled one-on-one meetings earlier in the week and has scheduled meetings next week, but did not participate in a conference yesterday based on counsel's advice, adds the analyst. The company has previously chosen not to convert to a C-Corp as this would involve either trigging a substantial tax bill for unitholders, or the tax bill being borne by the new C-Corp in the form of higher go forward tax rates, "neither of which is acceptable," says Conder. The analyst believes this same dilemma would face Six Flags in the event of an acquisition. For his part, Conder has yet to find any type of multiple stock class structures that would work and avoid the ability to defer a transactional tax bill to either unitholders or the surviving C-Corp. In addition, Six Flags launched a repricing of its $798M term loan due 2026 on September 30, Conder points out. It would be "strange that the company would do this ahead of a major acquisition bid," he says. As such, the analyst reiterates his view that a Six Flags acquisition of Cedar Fair is "highly unlikely." He also believes the recent pullback in Six Flags shares is "overdone and unwarranted." Candor would be an "aggressive" of Six Flags ahead of what he expects will be "solid" Q3 results from both companies. And if the recent buyout talk subsides, the analyst sees only a "modest" $2-$3 per share give back in Cedar Fun. He keeps an Outperform rating on both stocks.
10/04/19
KEYB
10/04/19
NO CHANGE
KEYB
Overweight
Keybanc says bid near $85 per share would be hard for Cedar Fair not to consider
After Reuters reported that Cedar Fair (FUN) has rejected a $70 stock-and-cash offer made by Six Flags (SIX) as too low, Keybanc analyst Brett Andress said his conversations with Cedar Fair lead him to conclude that the company is not for sale, "but everything does have a price." He thinks a bid near $85 per share would be "hard for Cedar Fair unitholders to turn down (or at least seriously consider)," Andress tells investors. While a theoretical $85 bid might be "doable," it would require a massive amount of equity "and this $85 scenario is still a far stretch," said the analyst, who admits that he "also thought SIX's initial idea to even approach FUN was a stretch." Andress has Overweight ratings on both Six Flags and Cedar Fair shares.
NAVI Navient
$12.09

0.12 (1.00%)

07/25/19
WEDB
07/25/19
DOWNGRADE
WEDB
Neutral
Navient downgraded to Neutral from Outperform at Wedbush
07/25/19
07/25/19
DOWNGRADE
Target $14.5

Neutral
Navient downgraded to Neutral on valuation at Credit Suisse
As previously reported, Credit Suisse analyst Moshe Orenbuch downgraded Navient to Neutral from Outperform, while raising his price target on the shares to $14.50 from $14. The analyst cited valuation and his expectation private loan CPRs will rise further. Additionally, based on management's approach to capital return and expense reductions, he ascribes a lower probability to the outcome in which they cut costs rapidly enough to maintain/improve efficiency over the longer-term.
07/25/19
LEHM
07/25/19
NO CHANGE
Target $17
LEHM
Overweight
Navient price target raised to $17 from $14 at Barclays
Barclays analyst Mark DeVries raised his price target for Navient to $17 from $14 saying the company's Q2 results continued some of its positive momentum. In addition, Navient now expects a better private net interest margin given the current rate outlook, DeVries tells investors in a research note. He believes the stock's valuation remains attractive and keeps an Overweight rating on the name.
07/25/19
07/25/19
DOWNGRADE
Target $15.75

Neutral
Navient downgraded to Neutral on valuation at Wedbush
As previously reported, Wedbush analyst Henry Coffey downgraded Navient to Neutral from Outperform, with a $15.75 price target. The analyst cited valuation as the shares traded to within a shade of his price target on Wednesday and closed at a price level in which expected total return associated with holding the stock is about 8%.
IRBT iRobot
$55.39

-0.31 (-0.56%)

10/09/19
10/09/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Domino's Pizza (DPZ) downgraded to Hold from Buy at Argus with analyst John Staszak citing its worse than expected Q3 revenue and earnings along with its new 2-3 year outlook of global retail sales growth of 7%-10% - down from its prior 3-5 year outlook of 8%-12% growth. 2. FedEx (FDX) downgraded to Market Perform from Outperform at Bernstein. 3. Waters (WAT) downgraded to Underweight from Equal Weight at Barclays with analyst Jack Meehan saying as leading indicators of the macro environment continue to weaken, he sees risk to the outlook for Waters' Industrial sales exposure. 4. iRobot (IRBT) downgraded to Underperform from Market Perform at Raymond James with analyst Brian Gesuale saying he thinks Street models aren't reflecting the beginning of a meaningful commoditization cycle across the RVC category. 5. Lincoln Electric (LECO) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he still sees Lincoln Electric as "one of the highest quality businesses" in his coverage universe thanks to its strong management and leading technologies, but believes that the headwinds in the company's end market will limit the upside for investors in the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/19
JPMS
10/16/19
NO CHANGE
Target $69
JPMS
Neutral
iRobot price target lowered to $69 from $83 at JPMorgan
JPMorgan analyst Mark Strouse lowered his price target for iRobot (IRBT) to $69 from $83 and keeps a Neutral rating on the shares ahead of the company's Q3 results. The analyst expects "some quarter-to-quarter noise" in the second half of 2019 related to timing of Amazon (AMZN) orders, which he notes are expected to be unseasonably tilted towards Q4 owing to tariffs. In addition, initial reviews for the competing high-end Shark RVC are mostly positive, which may lead to share loss for iRobot during the key holiday season, Strouse tells investors in a pre-earnings research note. While iRobot has sued Shark for patent infringement, the analyst does not expect a decision prior to year-end, "meaning that holiday sales may still be at risk."
10/16/19
SBSH
10/16/19
NO CHANGE
SBSH
Neutral
Citi opens negative catalyst watch on iRobot, citing Shark litigation
Citi analyst Asiya Merchant opened a negative catalyst watch on iRobot after the company filed a motion for a preliminary injunction against the Shark IQ Robot, claiming that SharkNinja infringed on three patents related to its Roomba i7+. The analyst noted that when iRobot previously won an exclusion order in December 2018 to bar Hoover and bobSweep products from being imported into the U.S., iRobot saw "a significant increase" in litigation expenses, to about $4.3B per year from $0.6B in the prior year. Merchant, who believes that the new Shark litigation could drive increased operating expenses for the company over the next few quarters, keeps a Neutral rating on iRobot shares.
10/09/19
RAJA
10/09/19
DOWNGRADE
RAJA
Underperform
Raymond James cites emergence of pricing war in iRobot downgrade
Raymond James analyst Brian Gesuale downgraded iRobot to Underperform from Market Perform, telling investors in a research note that he thinks Street models aren't reflecting the beginning of a meaningful commoditization cycle across the RVC category. As growth rates and profits decelerate and its workhorse product, the Roomba, is finally feeling "fatigue" after 17 years of service.

TODAY'S FREE FLY STORIES

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.